Jennifer Y. Ge

Jennifer Y. Ge

Auto-generated profile, based on publicly available information

Jennifer Y. Ge

Memorial Sloan Kettering Cancer Center 1 Gynecologic Medical Oncology Service, Department of Medicine New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJennifer Y. Ge
Jennifer Y. Ge
SSShaokun Shu
Shaokun Shu
MKMijung Kwon
Mijung Kwon
BJBojana Jovanović
Bojana Jovanović
KMKatherine Murphy
Katherine Murphy
KPKornelia Polyak
Kornelia Polyak
BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor evolution. Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxel, a microtubule inhibitor, synergize with the BET inhibitor JQ1 in TNBC lines. High-complexity DNA barcoding and mathematical modeling indicate a high rate of de novo acquired resistance to these drugs relative to pre-existing resistance. We demonstrate that the combination of JQ1 and palbociclib induces cell division errors, which can increase the chance of developing aneuploidy. Characterizing acquired resistance to combination treatment at a single cell level shows heterogeneous mechanisms including activation of G1-S and senescence pathways. Our results establish a rationale for further investigation of combined BET and CDK4/6 inhibition in TNBC and suggest novel mechanisms of action for these drugs and new vulnerabilities in cells after emergence of resistance.

6 July 2021 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
JGJennifer Y. Ge
Jennifer Y. Ge
BOBeth Overmoyer
Beth Overmoyer
Inflammatory breast cancer (IBC) is a rare type of breast cancer that is associated with poor outcomes compared with non-IBC. Overexpression of HER2 is enriched in IBC, and those with HER2-positive disease have a relatively favorable prognosis, with improved survival over the last two decades driven by the advent of novel targeted therapies. Here, we present two patients who have survived for over 10 years after being diagnosed with de novo metastatic HER2-positive IBC. We review the data for the treatments available for metastatic HER2-positive IBC and the evolving treatment recommendations for this disease.

25 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MRMaria M. Rubinstein
Maria M. Rubinstein
JGJennifer Y. Ge
Jennifer Y. Ge
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Purpose: Copy number–high (CN-H)/p53-abnormal endometrial cancers are high-grade uterine malignancies characterized by TP53 mutations, copy-number alterations, mismatch repair proficiency (MMRp), and absence of POLE mutations. A subset may be homologous recombination deficient (HRD), potentially conferring sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. We aimed to test the combination of PARP and immune checkpoint inhibitors in this subgroup, leveraging possible synergy from immune priming. Patients and Methods: We conducted a single-arm, open-label, phase II trial evaluating the efficacy and safety of olaparib (300 mg orally twice daily) plus pembrolizumab (200 mg intravenously every 3 weeks) in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Eligible patients had p53-abnormal, MMRp, and POLE-negative disease and up to 3 prior lines of therapy. The primary endpoint was the best overall response rate (ORR) at 24 weeks. Results: Of the 25 patients evaluable for efficacy, 2 patients achieved a complete response, and 6 achieved a partial response, resulting in an ORR of 32% [90% one-sided confidence interval (CI), 19.6%–100%]. The median duration of response was 11.2 months (80% two-sided CI, 6.4–11.9). The median progression-free survival was 3.9 months (80% two-sided CI, 2.1–5.8), and the median overall survival was 16.5 months (80% two-sided CI, 9.6–23.6). No new safety signals were identified. Genomic analyses suggested that responders had a numerically higher frequency of HRD tumors than nonresponders (50% vs. 17%). Conclusions: The combination of olaparib plus pembrolizumab has promising activity with durable responses in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Molecular biomarkers may be helpful for patient selection in future studies of this combination.

15 June 2026
Verified
Other
Open access
PDF file
MRMaria M. Rubinstein
Maria M. Rubinstein
JGJennifer Y. Ge
Jennifer Y. Ge
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Comparison of HRD scores in primary vs. recurrent disease and untreated vs. previously treated disease.


15 June 2026
Verified
Other
Open access
PDF file
MRMaria M. Rubinstein
Maria M. Rubinstein
JGJennifer Y. Ge
Jennifer Y. Ge
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Exploratory analysis of the three components of the HRD score.